Inactive Instrument

All News Actavis Inc Nyse

Equities

US9426831031

End-of-day quote Nyse Other stock markets
- ^USD	-

Mar. 05	Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	CI
2023	Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	Apr. 01	AQ
Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	Mar. 05	CI
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence	23-09-18	CI
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic)	23-08-30	CI
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM®	23-05-15	CI
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc	23-01-18	CI
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection	23-01-17	CI
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting	22-10-07	CI
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body	22-08-31	CI
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition	22-08-03	CI
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics	22-06-13	CI
Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	22-04-20	AQ
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	22-04-06	AQ
PatientFi Expands Partnership with Allergan Aesthetics	22-04-06	CI
AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	22-03-22	AQ
Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million.	21-12-15	CI
Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	21-12-10	AQ
Allergan Aesthetics to Present Data from its Aesthetic Portfolio at the 2021 American Society for Dermatologic Surgery Virtual Meeting	21-11-19	CI
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia	21-10-27	AQ
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia	21-10-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Actavis Inc Nyse

Equities

US9426831031

All News

Filters